Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Cervical Cancer

Free Subscription 22.09.2025 1 Adv Biomed Res 1 Am J Obstet Gynecol 1 Am J Surg Pathol 1 Ann Oncol 5 Asian Pac J Cancer Prev 1 Br J Health Psychol 1 Brachytherapy 1 Bull Cancer 1 Cancer Control 1 Cancer Epidemiol Biomarkers Prev 1 Curr Med Imaging 2 Diagnostics (Basel) 1 Ecancermedicalscience 1 Elife 1 Eur J Cancer 1 Front Artif Intell 1 Front Oncol 1 Gac Sanit 6 Gynecol Oncol 1 Gynecol Oncol Rep 1 Healthcare (Basel) 2 Histol Histopathol 1 Hum Cell 3 Int J Mol Sci 2 J Clin Med 1 J Health Psychol 1 J Obstet Gynaecol Can 1 J Racial Ethn Health Disparities 1 JAMA Netw Open 1 JMIR Public Health Surveill 1 LGBT Health 1 Narra J 1 Oncoimmunology 1 PLoS One 1 Radiol Oncol 1 Risk Manag Healthc Policy 1 Sci Rep 1 Sichuan Da Xue Xue Bao Yi Xue Ban 1 Spectrochim Acta A Mol Biomol Spectrosc 4 Vaccine 1 Womens Health (Lond) 3 Zhonghua Yu Fang Yi Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Biomed Res

1. TAVAKOLIAN S, Atani ZR, Faghihloo E
   Assessing the Biological Markers of MiRNA-9 and 192 Expression Levels in Cervical Cancer.
   Adv Biomed Res. 2025;14:91.
   PubMed         Abstract available
   
   

   
   Am J Obstet Gynecol

2. OSTENFELD EB, Bjornholt SM, Sponholtz SE, Froding LP, et al
   Long-term lymphedema and quality of life following lymph node staging in early cervical cancer: 3 years follow-up in the prospective multicenter SENTIREC CERVIX study.
   Am J Obstet Gynecol. 2025 Sep 15:S0002-9378(25)00674.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

3. TALIA KL, Hawkes D, Zhang G, Jamison J, et al
   HPV42: A Common Low-Risk HPV Type Associated With Distinctive Cervicovaginal and Cutaneous Neoplasia.
   Am J Surg Pathol. 2025;49:992-1003.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. RYU SY, Deng W, Albuquerque K, Koh WJ, et al
   Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008.
   Ann Oncol. 2025 Sep 12:S0923-7534(25)04700-3. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Asian Pac J Cancer Prev

5. DE SOUSA LR, Sousa EDLS, Palmeira ACDC, Palmeira MS, et al
   The Role of lncRNAs in the Epithelial-Mesenchymal Transition in Cervical Cancer: A Narrative Review.
   Asian Pac J Cancer Prev. 2025;26:3137-3143.
   PubMed         Abstract available
   
   
6. MUNIZAR M, Ar Royan H, Yolanda F
   Barriers to Cervical Cancer Screening through Pap Smear Examination among Women Attending the Gynecology Polyclinic at Dr. Zainoel Abidin General Hospital in 2024: A Cross-Sectional Study.
   Asian Pac J Cancer Prev. 2025;26:3309-3317.
   PubMed         Abstract available
   
   
7. PLUTHIKARMPAE N, Thongjit S
   Prevalence of Human Papillomavirus Infection in Nakhon Ratchasima, Northeastern Thailand.
   Asian Pac J Cancer Prev. 2025;26:3353-3358.
   PubMed         Abstract available
   
   
8. NATHANIEL V B, Chandraguthi SG, Rao S, Lewis S, et al
   Feasibility Study of Using Kv-Cone Beam CT Images as Patient Specific Quality Assurance Tool.
   Asian Pac J Cancer Prev. 2025;26:3359-3368.
   PubMed         Abstract available
   
   
9. SUWANTAROJ J, Sripan P, Kallawicha K, Tso J, et al
   The Utilization of Human Papillomavirus Testing for Cervical Cancer Screening in Thailand: A Comparison of Screening with and without Self-sampling Samples.
   Asian Pac J Cancer Prev. 2025;26:3469-3475.
   PubMed         Abstract available
   
   

   
   Br J Health Psychol

10. SHPENDI S, Norman P, Gibson-Miller J, Webster R, et al
    Cervical screening attendance in young women and people with a cervix: An application of the COM-B model.
    Br J Health Psychol. 2025;30:e70016.
    PubMed         Abstract available
    
    

    
    Brachytherapy

11. ARYASOMAYAJULA C, Xu MJ, Hui CB, Wong ML, et al
    Cancer control and toxicity results of chemoradiation for cervical cancer using a three-fraction HDR brachytherapy boost.
    Brachytherapy. 2025 Sep 16:S1538-4721(25)00285.
    PubMed         Abstract available
    
    

    
    Bull Cancer

12. HABERSTICH M, Rodrigues M
    [Pembrolizumab with chemoradiotherapy in high risk locally advanced cervical cancer].
    Bull Cancer. 2025 Sep 12:S0007-4551(25)00379.
    PubMed        
    
    

    
    Cancer Control

13. AFOLABI EK, Olaogun AAE
    Assessment of the Quality of Cervical Cancer Prevention Services in Southwest Nigeria: A Cross-Sectional Study Using Donabedian's Quality Framework.
    Cancer Control. 2025;32:10732748251333036.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

14. LEFEUVRE C, De Pauw H, Dhollander N, Le Duc Banaszuk AS, et al
    Mailing vaginal or urine self-sampling kits versus conventional invitation letters: a randomised trial to assess the effect on cervical cancer screening attendance.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Curr Med Imaging

15. LI S, Chen P, Zhang J, Wang B, et al
    MBLEformer: Multi-Scale Bidirectional Lesion Enhancement Transformer for Cervical Cancer Image Segmentation.
    Curr Med Imaging. 2025 Sep 16. doi: 10.2174/0115734056357180250516022218.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

16. APOORVA, Handa V, Batra S, Arora V, et al
    Deep Learning-Based DNA Methylation Detection in Cervical Cancer Using the One-Hot Character Representation Technique.
    Diagnostics (Basel). 2025;15:2263.
    PubMed         Abstract available
    
    
17. IBIS K, Ilgin C, Suncak L, Akbas CK, et al
    Prognostic Significance of Nomogram and T-Score in Locally Advanced Cervical Cancer Patients Treated with Curative Chemoradiotherapy and Image-Guided Brachytherapy: A Single-Center Retrospective Study.
    Diagnostics (Basel). 2025;15:2142.
    PubMed         Abstract available
    
    

    
    Ecancermedicalscience

18. NACIRI M, Aouzah FE, El Ghanmi A, Ghazi B, et al
    BRCA mutation and multiple primary malignancies: a rare case of recurring triple-negative breast cancer and cervical cancer.
    Ecancermedicalscience. 2025;19:1939.
    PubMed         Abstract available
    
    

    
    Elife

19. YIN Z, Feng T, Xu Q, Dai W, et al
    Monitoring circulating cell-free HPV DNA in metastatic or recurrent cervical cancer: clinical significance and treatment implications.
    Elife. 2025;13:RP101887.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

20. RAMOS-CASALLAS A, Cardona-Mendoza A, Perdomo-Lara SJ, Rico-Mendoza A, et al
    Performance evaluation of machine learning models in cervical cancer diagnosis: Systematic review and meta-analysis.
    Eur J Cancer. 2025;229:115768.
    PubMed         Abstract available
    
    

    
    Front Artif Intell

21. FAN J, Xiao W, Yan Z, Ouyang Q, et al
    Accuracy of AI chatbots in answering frequently asked questions on cervical cancer.
    Front Artif Intell. 2025;8:1655303.
    PubMed         Abstract available
    
    

    
    Front Oncol

22. LI D, Yan B, Liao K, Huang J, et al
    Multi-omics modality completion and knowledge distillation for drug response prediction in cervical cancer.
    Front Oncol. 2025;15:1622600.
    PubMed         Abstract available
    
    

    
    Gac Sanit

23. BESO DELGADO M, Castan Cameo S, Requena Menendez A, Ibanez Cabanell J, et al
    [Implementation of population-based self-sampling cervical cancer screening. Pilot study in the Valencian Community].
    Gac Sanit. 2025;39:102522.
    PubMed         Abstract available
    
    

    
    Gynecol Oncol

24. SCHAAFSMA M, Schuurman TN, Bekkers RLM, Dunne FR, et al
    The risk for residual AIS/CIN3+ after the first conservative surgical procedure for cervical adenocarcinoma in situ - A Dutch retrospective cohort study.
    Gynecol Oncol. 2025;200:44-50.
    PubMed         Abstract available
    
    
25. RAGLAND K, Pogue J, Simiele E, Simiele S, et al
    The use of transrectal ultrasound to improve gynecologic interstitial applicator implantation.
    Gynecol Oncol. 2025;200:88-95.
    PubMed         Abstract available
    
    
26. ZHOU N, Beavis AL, Lin LL, Neibart SS, et al
    Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S.
    Gynecol Oncol. 2025;200:193-202.
    PubMed         Abstract available
    
    
27. NEIBART S, Zhou N, Chino J, Earles T, et al
    Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment.
    Gynecol Oncol. 2025;200:186-192.
    PubMed         Abstract available
    
    
28. NEIBART SS, Lin LL, Einstein MH, Teoh D, et al
    Minimum standards for radiation therapy in the treatment of cervical cancer in the U.S.: A consensus statement by SGO, ASTRO, and ABS addressing the WHO Cervical Cancer Elimination Campaign goals.
    Gynecol Oncol. 2025;200:180-185.
    PubMed         Abstract available
    
    
29. MATSUBARA M, Otani T, Kawakami F, Koike A, et al
    Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group.
    Gynecol Oncol. 2025;200:112-121.
    PubMed         Abstract available
    
    

    
    Gynecol Oncol Rep

30. OKUMA Y, Ikeda Y, Kobayashi O, Kamata S, et al
    Development of immune radiotherapy with yttrium by targeting Frizzled homologue 10 (FZD10) in cervical cancer.
    Gynecol Oncol Rep. 2025;59:101736.
    PubMed         Abstract available
    
    

    
    Healthcare (Basel)

31. PASCA NM, Taut D, Pintea S, Baban AS, et al
    Emotional, Cognitive, and Social Factors Influencing Romanian Women's Intention to Undergo Cervical Cancer Screening: A Mixed-Method Study.
    Healthcare (Basel). 2025;13:2147.
    PubMed         Abstract available
    
    

    
    Histol Histopathol

32. BOLLEN I, Bernhardt M, Thiesler T, Winterhagen FI, et al
    The prognostic value of adipokine receptors leptinR and adiponectinR1 in obesity-inducible solid tumours.
    Histol Histopathol. 2025;40:1577-1596.
    PubMed         Abstract available
    
    
33. YAMAMOTO T, Okamura Y, Kato Y, Masui K, et al
    Suppressive role of fukutin on cell proliferation in uterine cervical carcinoma in relation to Aurora-A kinase.
    Histol Histopathol. 2025;40:1555-1568.
    PubMed         Abstract available
    
    

    
    Hum Cell

34. YAMADA H, Yokoi A, Asano-Inami E, Kitagawa M, et al
    Establishment of KGAS, a cell line derived from gastric-type adenocarcinoma of the uterine cervix.
    Hum Cell. 2025;38:159.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

35. BOLDEANU L, Assani MZ, Boldeanu MV, Silosi I, et al
    Cervical Cancer in the Era of HPV: Translating Molecular Mechanisms into Preventive Public Health Action.
    Int J Mol Sci. 2025;26:8463.
    PubMed         Abstract available
    
    
36. BARTUSIK-AEBISHER D, Saad MA, Przygorzewska A, Woznicki P, et al
    Latest Nanoparticles to Modulate Hypoxic Microenvironment in Photodynamic Therapy of Cervical Cancer: A Review of In Vivo Studies.
    Int J Mol Sci. 2025;26:8503.
    PubMed         Abstract available
    
    
37. OZDEMIR I, Afsin Y, Tuncer MC, Ozturk S, et al
    Combined Hesperidin and Doxorubicin Treatment Induces Apoptosis and Modulates Inflammatory Cytokines in HeLa Cervical Cancer Cells.
    Int J Mol Sci. 2025;26:8753.
    PubMed         Abstract available
    
    

    
    J Clin Med

38. BARBU MA, Ghigeanu M, Bahaa-Eddin S, Michire A, et al
    Impact of Chemoradiotherapy on Quality of Life in Cervical Cancer Patients: A Prospective Cohort Study.
    J Clin Med. 2025;14:6023.
    PubMed         Abstract available
    
    
39. SZABO V, Varbiro S, Kalas N, Vida B, et al
    The Lymphocyte-to-Monocyte Ratio (LMR) as a Novel Biomarker for Cervical Cancer Risk Stratification in Conization Patients.
    J Clin Med. 2025;14:6057.
    PubMed         Abstract available
    
    

    
    J Health Psychol

40. BIANCHI M, Capasso M, Donizzetti AR, Caso D, et al
    Navigating women's cancer prevention: Two cross-sectional studies to investigate psychosocial antecedents of cervical and breast cancer screening attendance.
    J Health Psychol. 2025;30:2970-2983.
    PubMed         Abstract available
    
    

    
    J Obstet Gynaecol Can

41. LIAO ZY, Chen Y, OuYang Z
    Umbilical port site metastasis after laparoscopic radical hysterectomy for cervical cancer.
    J Obstet Gynaecol Can. 2025 Sep 12:103109. doi: 10.1016/j.jogc.2025.103109.
    PubMed        
    
    

    
    J Racial Ethn Health Disparities

42. FISHER S, Agenor M
    Socioeconomic Inequities in Pap Test Use Among Black Women in the United States: An Intersectional Approach.
    J Racial Ethn Health Disparities. 2025;12:3451-3459.
    PubMed         Abstract available
    
    

    
    JAMA Netw Open

43. SUK R, Lin YY, Dilley S, Chandler R, et al
    Survival by Treatment Recommendation and Receipt Among Older Patients With Early-Stage Cervical Cancer.
    JAMA Netw Open. 2025;8:e2532206.
    PubMed         Abstract available
    
    

    
    JMIR Public Health Surveill

44. BAYKEMAGN ND, Aweke MN, Mesfin A, Baffa LD, et al
    Identifying Predictors of Cervical Cancer Screening Uptake in Sub-Saharan Africa Using Machine Learning: Cross-Sectional Study.
    JMIR Public Health Surveill. 2025;11:e71677.
    PubMed         Abstract available
    
    

    
    LGBT Health

45. MEYER CM, Rankin K, Handler A, Barshop W, et al
    Well-Woman Visits and Cervical Cancer Screening at the Intersection of Sexual Orientation and Race/Ethnicity Among Illinois Women.
    LGBT Health. 2025 Sep 16. doi: 10.1177/23258292251379503.
    PubMed         Abstract available
    
    

    
    Narra J

46. SAVIRA M, Farniga A, Ilmiah Z, Rachmadina R, et al
    Genetic variations of the L2 gene in human papillomavirus (HPV) type 16 from cervical cancer patients in Sumatra region, Indonesia.
    Narra J. 2025;5:e1653.
    PubMed         Abstract available
    
    

    
    Oncoimmunology

47. POLTEN R, Kutle I, Stalp JL, Hachenberg J, et al
    Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts.
    Oncoimmunology. 2025;14:2556714.
    PubMed         Abstract available
    
    

    
    PLoS One

48. CHEN D, Wu H, Huang F, Tan K, et al
    Prognostic follow-up of high-grade squamous intraepithelial lesions of the cervix near the conization margin: A retrospective cohort study.
    PLoS One. 2025;20:e0331184.
    PubMed         Abstract available
    
    

    
    Radiol Oncol

49. RADULOVIC MK, Ostrbenk A, Poljak M, Strojan-Flezar M, et al
    Human papillomavirus (HPV) genotyping and prognostic value of HPV E4 protein and transcription factors NANOG and SOX11 in atypical p16 patchy squamous epithelium of cervix.
    Radiol Oncol. 2025;59:391-402.
    PubMed         Abstract available
    
    

    
    Risk Manag Healthc Policy

50. HUANG M, Chen X, Lin X, Yang Y, et al
    Prediction Models of Microinvasive Cervical Cancer in High-Grade Squamous Intraepithelial Lesion Treatment by Loop Electrosurgical Excision Procedure.
    Risk Manag Healthc Policy. 2025;18:2921-2934.
    PubMed         Abstract available
    
    

    
    Sci Rep

51. SOLIS-PONCE L, Stosic M, Curico G, Espetia S, et al
    Genotype distribution and molecular characterization of HPV in the Peruvian amazon: insights into prevalence, lineage diversity, and viral integration.
    Sci Rep. 2025;15:32535.
    PubMed         Abstract available
    
    

    
    Sichuan Da Xue Xue Bao Yi Xue Ban

52. YANG Y, Li C, Jia S, Wang Y, et al
    [TruScreen Combined With High-Risk Human Papillomavirus Testing vs Thinprep Cytology Test Combined With High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: A Comparative Clinical Study].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2025;56:852-857.
    PubMed         Abstract available
    
    

    
    Spectrochim Acta A Mol Biomol Spectrosc

53. LI N, Yuan H, Yan W, Zhang MM, et al
    Discovery of an acridine-based fluorescent ligand for selectively targeting mitochondrial G-quadruplexes DNA and triggering cervical cancer cell death.
    Spectrochim Acta A Mol Biomol Spectrosc. 2025;346:126844.
    PubMed         Abstract available
    
    

    
    Vaccine

54. BAUSSANO I, Tenet V, Baghdasarova K, Harutyunyan Z, et al
    HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys.
    Vaccine. 2025;62:127405.
    PubMed         Abstract available
    
    
55. TAO T, Ni Y, Shi N, Yang X, et al
    Human papillomavirus vaccination coverage and willingness among women in mainland China: A meta-analysis based on the COM-B model.
    Vaccine. 2025;62:127519.
    PubMed         Abstract available
    
    
56. CARLTON JG, Pamba D, Ryan N, Olomi W, et al
    Facilitators and barriers to implementation of HPV vaccination in Tanzania: a mixed-methods study exploring perspectives from national, subnational, and community stakeholders, 2018-2023.
    Vaccine. 2025;62:127560.
    PubMed         Abstract available
    
    
57. LI J, Zhao D, Zi T, Huang R, et al
    Evolving trends in HPV vaccination coverage among women aged 9-45 in Chengdu, China: insights from 2017 to 2023.
    Vaccine. 2025;62:127579.
    PubMed         Abstract available
    
    

    
    Womens Health (Lond)

58. LE A, Smith LS, Wheeler SB, Giannone K, et al
    Implementing self-collection for primary human papillomavirus testing: Perspectives on implications for federally qualified health center patient populations.
    Womens Health (Lond). 2025;21:17455057251362581.
    PubMed         Abstract available
    
    

    
    Zhonghua Yu Fang Yi Xue Za Zhi

59. 
    [Expert consensus on comprehensive prevention and control strategies for human papillomavirus associated diseases].
    Zhonghua Yu Fang Yi Xue Za Zhi. 2025;59:1362-1371.
    PubMed         Abstract available
    
    
60. ZHU YW, Chen YP, Liang YX, Wang SY, et al
    [Comparative analysis of free HPV vaccination programs across countries with different income levels worldwide: from implementation to evaluation].
    Zhonghua Yu Fang Yi Xue Za Zhi. 2025;59:1503-1511.
    PubMed         Abstract available
    
    
61. CHEN YP, Deng X, Wang Y, Zhu YW, et al
    [Practices and considerations on the free HPV vaccination program for eligible girls in Zhejiang Province under the global initiative to accelerate cervical cancer elimination].
    Zhonghua Yu Fang Yi Xue Za Zhi. 2025;59:1495-1502.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.